Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

9 Jul 2013
by Working Group

Posted in Announcements, TB Drug Development, TB News

Otsuka Begins Paediatric MDR-TB Trials

otsuka

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB). Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a dispersible formulation for use with younger children and infants.

1 Jul 2013
by Working Group

Posted in Action, TB Drug Development, TB News

TAG Releases 2013 Pipeline Report

Click here to access full report

HIV i-Base and Treatment Action Group (TAG) called on global and national leaders, research sponsors, and regulatory authorities to work together to make the best HIV, HCV, and TB drugs, diagnostics, and vaccines accessible as fast as possible, according to a report released today at the 7th International AIDS Society (IAS) Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur, Malaysia.

13 Jun 2013

WHO Issues Interim Guidance on the Use of Bedaquiline to Treat

who-logo

The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB).

TB R&D Update: Vitamin C Kills Tuberculosis in vitro

ncomms2898-i1

This week we highlight a study out of Dr. William Jacobs, Jr.’s lab showing that “vitamin C, a compound known to drive the Fenton reaction, sterilizes cultures of drug-susceptible and drug-resistant Mycobacterium tuberculosis, the causative agent of tuberculosis.” Additional links to other news and articles related to TB R&D are included.

16 Apr 2013

Medecins Sans Frontieres/Doctors Without Borders Scientific Day May 10th

msfscience day

MSF Scientific Day is a unique opportunity to showcase medical and scientific research carried out in MSF programmes around the world. Presenting and debating the findings from our research is vital to improve the quality of our humanitarian programmes. There will be several topic s on tuberculosis.

16 Apr 2013
by Working Group

Posted in Announcements, market access, TB News

New Database Tracks Health Technology Innovations

Click here to check out entire database.

The Center for Health Market Innovations (CHMI) has compiled profiles on over 1,200 programs and counting. For TB innovations, the CHMI database contains 58 programs that work on TB in 33 countries.

TB Edition of The Lancet Infectious Diseases

Click to access links and audio from Lancet ID TB Edition

To commemorate World TB Day 2013, The Lancet Infectious Diseases publishes a Series of papers on tuberculosis, a disease that has long plagued human beings and was declared a global emergency in 1993 by WHO.

Get Ready for World TB Day March 24, 2013!

WTBD 2013

World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Included is a list of publications, news items, events, and links related to TB and World TB Day 2013.

4 Feb 2013

TB R&D Weekly Update: TB Vaccine Efficacy Trial Yields Key Insights and Poor Results

8b5b658d4988a246e72a12cd33f5

The results of the first TB vaccine efficacy trial in over 90 years was released today showing that the vaccine candidate MVA85A when given as a booster did not provide added protection to infants who had already received BCG. The trial adds scientific value to the field and enhances the field’s understanding and ability in conducting large-scale TB vaccine trials. Additional links to TB R&D news are included.

Bedaquiline Receives Accelerated Approval from the FDA for MDR-TB Rx

FDA-Logo1

The FDA granted Janssen’s TB drug Bedaquiline accelerated approval for treatment of MDR-TB. A link is provided to the FDA press release and Janssen’s full press release is included.